Enterprise Associates 12, L... Net Worth

The estimated Net Worth of Enterprise Associates 12, L... is at least $7.83 Millón dollars as of 26 November 2019. Enterprise L owns over 1,283,919 units of Zosano Pharma Corp stock worth over $2,391,587 and over the last 8 years Enterprise sold ZSAN stock worth over $5,433,629.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Enterprise L ZSAN stock SEC Form 4 insiders trading

Enterprise has made over 3 trades of the Zosano Pharma Corp stock since 2017, according to the Form 4 filled with the SEC. Most recently Enterprise sold 1,283,919 units of ZSAN stock worth $3,222,637 on 26 November 2019.

The largest trade Enterprise's ever made was buying 2,000,000 units of Zosano Pharma Corp stock on 18 December 2017 worth over $10,000,000. On average, Enterprise trades about 1,461,305 units every 339 days since 2017. As of 26 November 2019 Enterprise still owns at least 4,270,691 units of Zosano Pharma Corp stock.

You can see the complete history of Enterprise L stock trades at the bottom of the page.

Insiders trading at Zosano Pharma Corp

Over the last 10 years, insiders at Zosano Pharma Corp have traded over $5,506,679 worth of Zosano Pharma Corp stock and bought 790,627 units worth $1,835,090 . The most active insiders traders include M James Barrett, Enterprise Associates 12, L... y Steve Elms. On average, Zosano Pharma Corp executives and independent directors trade stock every 60 days with the average trade being worth of $44,258. The most recent stock trade was executed by Christine Matthews on 6 June 2022, trading 82 units of ZSAN stock currently worth $58.

What does Zosano Pharma Corp do?

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine.

Complete history of Enterprise L stock trades at Proteostasis Therapeutics Inc y Zosano Pharma Corp

Zosano Pharma Corp executives and stock owners

Zosano Pharma Corp executives and other stock owners filed with the SEC include:

• Steven Lo,
  Sr. VP of Operations, Pres, CEO & Director
• Dr. Donald J. Kellerman,
  VP of Clinical Devel. & Medical Affairs
• Kleanthis Xanthopoulos,
  Independent Director
• Kenneth Greathouse,
  Independent Director
• Steven Elms,
  Independent Director
• Joseph Hagan,
  Director
• Linda Grais,
  Director
• Thorsten von Stein,
  Chief Medical Officer
• Eric Scharin,
  Vice President - Technical Operations
• Dushyant Pathak,
  Senior Vice President - Business Development
• Christine Matthews,
  Chief Financial Officer, Principal Financial Officer
• Steven Lo,
  Chief Executive Officer, Director
• John Walker,
  Chairman of the Board
• Kristina Warga,
  VP & Corp. Controller
• Lu Liu,
  VP of Technical Operations
• Jeffrey L. Quillen,
  Sec.
• Hayley Lewis,
  Sr. VP of Operations
• Christine Matthews,
  Chief Financial Officer
• Capital Iv, Lp Aisling Capi...,
  
• Winnie Wing Kei Tso,
  Chief Financial Officer
• Georgia Erbez,
  Interim CFO
• Konstantinos Alataris,
  President
• M James Barrett,
  Director
• Enterprise Associates 12, L...,
  
• Troy Edward Wilson,
  Director
• Enterprise Associates 12, L...,
  
• Kathy M. Mc Gee,
  Director
• Capital Management, Llc Kaz...,
  
• Gregory David Kitchener,
  Chief Financial Officer
• Elaine Yang,
  Director
• Enterprise Associates 12, L...,
  
• Realty Trust Inc Bio Med Re...,
  
• Laxmi Peri,
  Sr. Vice President, Operations
• Hayley Lewis,
  See Remarks
• Steve Elms,
  Director
• Donald J Kellerman,
  VP, Clinical Dev & Med Affairs